Description Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading
etiology for chronic liver disease, affecting> 25% of the US and global populations. Up to 1 …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

Since the 2018 ISPAD guidelines on this topic, follow‐up of large cohorts from around the
globe have continued informing the current incidence and prevalence of co‐morbidities and …

This cohort analysis investigated the prevalence of nonalcoholic fatty liver disease (NAFLD)
and NAFLD with fibrosis at different stages, associated clinical characteristics, and …

Population‐based studies that estimate awareness of nonalcoholic fatty liver disease
(NAFLD) in the United States are scant. We aimed to understand public awareness of …

The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide, whereas that of
most other cancers is decreasing. Non-alcoholic fatty liver disease (NAFLD), which has …

Background: Early identification of those with NAFLD activity score≥ 4 and significant
fibrosis (≥ F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a …

Objective A simple combined score with liver stiffness, controlled attenuation parameter and
serum aspartate aminotransferase (AST), the FibroScan-AST (FAST) score, has been …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease in the United States and worldwide. The progressive form of NAFLD, nonalcoholic …

Importance The most important surrogate for increased risk of adverse clinical outcomes
among patients with nonalcoholic fatty liver disease (NAFLD) is the patient's stage of liver …